Trial Profile
A Randomized, Multicenter, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With Merck Aluminum Adjuvant or Without Merck Aluminum Adjuvant in Healthy Adults 18 to 70 Years of Age
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs V-710 (Primary) ; Aluminium hydroxyphosphate sulfate
- Indications Staphylococcal infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Merck Sharp & Dohme Corp.
- 19 Dec 2011 Results published in Vaccine.
- 24 Feb 2011 New trial record